352 related articles for article (PubMed ID: 28628251)
21. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
22. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
[TBL] [Abstract][Full Text] [Related]
23. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
24. Advances in the systemic treatment of metastatic melanoma.
Yushak M; Kluger HM; Sznol M
Oncology (Williston Park); 2013 May; 27(5):374-81. PubMed ID: 25184258
[TBL] [Abstract][Full Text] [Related]
25. A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
Wang C; Song DJ; Xu ZL; Xie SP; Hu JH
Exp Mol Med; 2017 Sep; 49(9):e383. PubMed ID: 28960212
[TBL] [Abstract][Full Text] [Related]
26. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.
Yang XL; Duo-Ji MM; Long ZW
J Cell Biochem; 2017 Dec; 118(12):4536-4547. PubMed ID: 28471499
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.
Toor K; Middleton MR; Chan K; Amadi A; Moshyk A; Kotapati S
BMC Cancer; 2021 Jan; 21(1):3. PubMed ID: 33402121
[TBL] [Abstract][Full Text] [Related]
29. Novel targets in the treatment of advanced melanoma: new first-line treatment options.
Culos KA; Cuellar S
Ann Pharmacother; 2013 Apr; 47(4):519-26. PubMed ID: 23548648
[TBL] [Abstract][Full Text] [Related]
30. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
[TBL] [Abstract][Full Text] [Related]
31. The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis.
CiRen B; Wang X; Long Z
Oncotarget; 2016 Dec; 7(49):81493-81511. PubMed ID: 27845904
[TBL] [Abstract][Full Text] [Related]
32. Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.
Halloush S; Alkhatib NS; Almutairi AR; Calamia M; Halawah H; Obeng-Kusi M; Hoyle M; Rashdan O; Koeller J; Abraham I
Ann Pharmacother; 2023 Sep; 57(9):1016-1024. PubMed ID: 36639851
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in advanced melanoma: a network meta-analysis.
Pyo JS; Kang G
Immunotherapy; 2017 May; 9(6):471-479. PubMed ID: 28472905
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
[No Abstract] [Full Text] [Related]
35. Systemic Therapy for Melanoma: ASCO Guideline.
Seth R; Messersmith H; Kaur V; Kirkwood JM; Kudchadkar R; McQuade JL; Provenzano A; Swami U; Weber J; Alluri KC; Agarwala S; Ascierto PA; Atkins MB; Davis N; Ernstoff MS; Faries MB; Gold JS; Guild S; Gyorki DE; Khushalani NI; Meyers MO; Robert C; Santinami M; Sehdev A; Sondak VK; Spurrier G; Tsai KK; van Akkooi A; Funchain P
J Clin Oncol; 2020 Nov; 38(33):3947-3970. PubMed ID: 32228358
[TBL] [Abstract][Full Text] [Related]
36. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
37. Dermatology update: The dawn of targeted treatment.
Fernandez A
Cleve Clin J Med; 2015 May; 82(5):309-20. PubMed ID: 25973879
[TBL] [Abstract][Full Text] [Related]
38. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
[TBL] [Abstract][Full Text] [Related]
39. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
Liu GF; Li GJ; Zhao H
J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
